Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Deucravacitinib is currently under regulatory review in multiple regions, including the U.S., Europe and Japan, and would be the first selective allosteric tyrosine kinase 2 (TYK2) inhibitor approved for the treatment of any disease
Moderate-to-severe plaque psoriasis affects about 35 per cent of patients. A key challenge is that many treatments stop working overtime and symptoms return
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Subscribe To Our Newsletter & Stay Updated
